- Status Complete
- Type Re-application
- Pre-PASC consultation -
- Pre-MSAC consultation -
- Outcome Supported
Application details
Reason for application
-
Service or technology in this application
ALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.
Medical condition this application addresses
ALK-positive advanced NSCLC.
Previous applications
Application documents
PICO confirmation
Public summary document
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Meetings to consider this application
- PASC meeting: -
- ESC meeting: 12 to 13 June 2014
- MSAC meeting:
- 3 October 2014
- 26 to 28 November 2014